Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRI-724 in HCV-induced Cirrhosis
NCT02195440Phase 1Completed
- Sponsor
- Tokyo Metropolitan Komagome Hospital
- Start
- Aug 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of foscenvivint in Liver cirrhosis (LC) (3 arms), sponsored by Tokyo Metropolitan Komagome Hospital. Primary endpoint: Adverse events and adverse drug reactions at 12 weeks. Started Aug 2014; status: completed.
02
Drugs
foscenvivint
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT02195440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195440.